Ahmed JD - Pieris Pharmaceuticals Chief VP

Pieris Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.1318) % which means that it has lost $0.1318 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8046) %, meaning that it created substantial loss on money invested by shareholders. Pieris Pharmaceuticals' management efficiency ratios could be used to measure how well Pieris Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.67 in 2024. Return On Capital Employed is likely to drop to -1.17 in 2024. At this time, Pieris Pharmaceuticals' Other Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 12.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 13.5 M in 2024.

Similar Executives

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts. Pieris Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. Pieris Pharmaceuticals (PIRS) is traded on NASDAQ Exchange in USA. It is located in 225 Franklin Street, Boston, MA, United States, 02110 and employs 46 people. Pieris Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Pieris Pharmaceuticals Leadership Team

Pieris Stock Performance Indicators

Additional Tools for Pieris Stock Analysis